A Membrane Fluidization Strategy Significantly Boosts Photodynamic Therapy and Antitumor Immunity of Porphyrin-Lipid Nanoparticles
Porphysomes (PS) are self-assembled porphyrin-lipid nanoparticles with intrinsic multifunctionality for cancer theranostics. We recently discovered that incorporating EDTA-conjugated lipids (EDTA-lipids) into lipid nanoparticle formulations significantly enhances intracellular uptake by modulating the cell membrane fluidity. To retain the favorable <i>in vivo</i> properties of PS while improving intracellular porphyrin delivery for effective photodynamic therapy (PDT), we developed a dual cellular- and vascular-enriched porphysome (DE-PS) containing 30 mol % cholesterol, 5 mol % PEG2000-DSPE, 27 mol % pyro-lipid, and 38 mol % EDTA-lipid. DE-PS demonstrated favorable pharmacokinetics (<i>t</i> <sub><sub>1</sub>/<sub>2</sub>β</sub> = 7.5 h), robust photostability (>99% fluorescence quenching), and strong serum stability over 24 h (>85% fluorescence quenching retained). Compared to PS, DE-PS resulted in an 11-fold increase in KB cancer cell uptake and achieved >95% PDT-induced cell death, in contrast to <5% with PS. Intravital imaging showed enhanced intratumoral porphyrin activation in DE-PS-treated mice, with stronger fluorescence signals observed in tumor vasculature and necrotic regions, leading to superior <i>in vivo</i> PDT efficacy across all drug-light-intervals. Notably, while low-dose PDT (25 J/cm<sup>2</sup>) with DE-PS had minimal impact on CT-26 tumor growth in immunodeficient NSG mice, it resulted in marked tumor suppression and prolonged survival in immunocompetent BALB/c mice, highlighting the importance of PDT-induced immune activation in the therapeutic response. A single DE-PS PDT treatment led to durable tumor-free survival exceeding 90 days. Upon CT-26 tumor rechallenge, previously cured mice rejected tumor regrowth, demonstrating development of long-lasting immunity without utilizing additional immunostimulants. This study highlights DE-PS as a promising next-generation porphysome-based photosensitizer platform for effective cancer phototherapy and immune modulation.
Authors
- Keegan Guidolin (ORCID: https://orcid.org/0000-0001-6482-8024)
- Tiffany Ho
- Yulin Mo
- Tracy Liu (ORCID: https://orcid.org/0000-0003-0671-8390)
- Ali Makky (ORCID: https://orcid.org/0000-0002-3807-0886)
- Mark Zheng (ORCID: https://orcid.org/0009-0003-0119-357X)
- Nahyun Kwon (ORCID: https://orcid.org/0000-0003-2442-5532)
- Michael S. Valic (ORCID: https://orcid.org/0000-0003-3488-023X)
- Lili Ding (ORCID: https://orcid.org/0009-0004-2987-1683)
- Gang Zheng (ORCID: https://orcid.org/0000-0002-0705-7398)
- Brian C. Wilson (ORCID: https://orcid.org/0000-0001-5543-666X)
- Layla Pires (ORCID: https://orcid.org/0000-0003-4558-5199)
- Juan Chen (ORCID: https://orcid.org/0000-0001-7515-5072)
- Yiming Yang (ORCID: https://orcid.org/0009-0008-5010-2749)
- Ashley Qian
Institutions
- West Virginia University (US)
- Centre National de la Recherche Scientifique (FR)
- University of Toronto (CA)
- Université Paris-Saclay (FR)
- Cancer Institute (WIA) (IN)
- Mitchell Institute (US)
- Princess Margaret Cancer Centre (CA)
- West Virginia State University (US)
- Texas A&M University (US)
Publication Details
- Journal
- ACS Nano Medicine
- Published
- 2025-10-16
- DOI
- https://doi.org/10.1021/acsnanomed.5c00053
- Citations
- 1
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 0.67